Clinical Trials Logo

Filter by:
NCT ID: NCT01281293 Completed - Epilepsy Clinical Trials

Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated

V-COMPAS
Start date: January 2011
Phase:
Study type: Observational

Vagus Nerve Stimulation (VNS) Therapy has been approved marked for the treatment of epilepsy since 1994. This post-market study is designed to follow the clinical course and outcomes for patients with refractory seizures treated with adjunctive VNS Therapy. Seizure frequency, seizure severity, side effects burden, depressive symptoms, global impressions, and health care utilization will be evaluated. The results of this study will provide data to guide physicians and their patients in the use of VNS Therapy for patients with refractory seizures who have failed initial trials of anti-epileptic drug (AED) therapy. The data being collected is not for the purposes of confirmatory assessment.

NCT ID: NCT01281059 Active, not recruiting - NAFLD Clinical Trials

Prediction of Severity of Liver Disease Non Alcoholic Fatty Liver Disease in Patients With Suspected NAFLD by a 13C Octanoate Breath Test

Start date: January 2011
Phase: N/A
Study type: Interventional

The Exalenz clinical investigation is a multicenter, non-randomized, blinded, study of the ¹³C-Octanaote breath test (OBT). The OBT is a non-invasive test for evaluation of disease severity in patients with suspected non alcoholic fatty liver disease (NAFLD) The purpose of the study is to demonstrate that the ¹³C-Octanaote Breath Test (OBT) can be used as an aid, in conjunction with other clinical information and medical history, for evaluating disease severity and detecting non alcoholic steatohepatitis(NASH) with a high probability. Retrospective analysis based on multivariable analysis will determined if and which demographic, clinical and biochemical or imaging techniques data can assist in addition to the data derived from OBT in differentiation of NASH, NAFL and possibly normals.

NCT ID: NCT01280305 Not yet recruiting - Schizophrenia Clinical Trials

Raloxifene in Treatment of Schizophrenia and Schizoaffective Disorder

RAL-S-01
Start date: March 2011
Phase: Phase 3
Study type: Interventional

The objective of the study is to evaluate the efficacy of raloxifene compared to placebo, as add-on to anti-psychotics in the treatment of post menopausal patients with schizophrenia.

NCT ID: NCT01279863 Not yet recruiting - Pneumonia Clinical Trials

VRI in Children With Acute Respiratory Symptoms.

VRI
Start date: February 2011
Phase: N/A
Study type: Observational

The VRI technology provides a radiation free dynamic image of the lung, by using a combination of well-known technologies, i.e. acoustic sensors, and a proprietary algorithm. The aim of the study is to determine if the VRI examination may contribute to the diagnosis and follow up of pneumonia in children, and therefore reduce the number of chest radiographs and the exposure to ionizing radiation. Children referred by ED for chest x-ray,for the evaluation of pneumonia, will undergo VRI as well. The two modalities will be read independently and then the findings will be compared, in order to asses the potential role of the VRI to the management of pneumonia in children.

NCT ID: NCT01279746 Completed - Hypoxia Clinical Trials

The Diagnosis of Occult Deep Vein Thrombosis of the Lower Extremities in Patients Presenting With Hypoxia

Start date: April 2010
Phase: N/A
Study type: Observational

The purpose of this study is to prove that bedside Ultrasound Compression is a useful screening tool for the diagnosis of occult deep vein thrombosis in patients presenting to the emergency room with hypoxia.

NCT ID: NCT01279564 Completed - Clinical trials for Endotracheal Intubation

Comparison Between Etview Tracheoscopic Ventilation Tube - TVT to Standard Endotracheal Intubation

Start date: February 2011
Phase: N/A
Study type: Interventional

Airway management is one of the most important tasks facing the physician, especially the anesthesiologist. Fast and correct performance of endotracheal intubations done as normal routine in the operating room, but can save life everywhere. To make intubation easier, several newly designed tubes and laryngoscopes are developed and tested every year. Their performance is evaluated subjectively by the acting anesthesiologist, and by using objective parameters such as speed of intubation, the force applied during latyngoscopy , or catecholeamines secretion during intubation as a stress parameter . The studies set for testing these parameters lead to establish accepted indications for the treatment of the airway in cases of anticipated and unanticipated difficult airway. In the present study we will compare the performance parameters of intubation using Etview Tracheoscopic Ventilation Tube - TVT to the standard tube, of which most of daily intubations are carried with. The Etview TVT is similar to the standard endotracheal tube; its outer dimensions and material is exactly as the standard tube, the difference is only the inner fiber of the camera.

NCT ID: NCT01278901 Not yet recruiting - Helicobacter Pylori Clinical Trials

The Effect of PPI Therapy on the Result of Helicobacter Pylori Diagnostic Tests

Start date: February 2011
Phase: N/A
Study type: Observational

STUDY PROTOCOL: The study will include 30 patients ages 18-80y that had a gastroscopy for various reasons. The patients should not be on PPI therapy . If during the gastroscopy there are some pathologies that require a second look endoscopy after some weeks of therapy (ulcers or esophagitis), the investigators will repeat the gastroscopy within a month. During the first gastroscopy a biopsy will be taken for histological examination and for a rapid urease test and an urea breath test will be done soon after the procedure. If one of the tests is positive the investigators postulate that the Helicobacter pylori is actually present. After the gastroscopy the patient is given a full dose of PPI (as indicated) and helicobacter tests are repeated in the next endoscopy (under PPI therapy) . Any positive test that become negative in the second endoscopy is considered false negative.

NCT ID: NCT01278706 Not yet recruiting - Infertility Clinical Trials

Endometrial Biopsy Protocol for In Vitro Fertilization (IVF)

Start date: January 2011
Phase: N/A
Study type: Interventional

Endometrial biopsy has been shown to improve IVF pregnancy and live birth rates. The optimal time of performing the biopsy is yet to be established. In this study, the investigators will compare different temporal timing of the biopsies with regards to the menstrual cycle and their affect on the success rates of the treatment.

NCT ID: NCT01278667 Recruiting - Clinical trials for Attention Deficit Hyperactivity Disorder

Methylphenidate and the Relations Between Emotional Processing and Social Functioning Among Children With ADHD

Start date: January 2011
Phase: N/A
Study type: Observational

Children with ADHD are in high risk to develope social difficulties. The present study will examine the emotional processing in those children. The main purpose is to investigate the connection between memory and recognition of facial expressions, how those abilities influence social functioning and if Methylphenidate influence the emotional processing. The study will include 80 children in ages 9-12 years, devided in 2 groups; children with ADHD treated with Methylphenidate, and healthy children without ADHD. The children will do computerized tasks that examine recognition and memory of facial expressions. Social function will be examined by questionnaires filled by parents and teachers.

NCT ID: NCT01277666 Completed - Crohn's Disease Clinical Trials

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

SHIELD-1
Start date: December 20, 2010
Phase: Phase 3
Study type: Interventional

This is a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of two doses (500 mg once daily and 500 mg twice daily) of GSK1605786A as compared to placebo over 12 weeks in adult subjects with moderately-to-severely active Crohn's disease. Efficacy will be assessed by proportion of subjects achieving response, defined as a decrease in Crohn's Disease Activity Index (CDAI) score of at least 100 points (clinical response). Clinical remission (CDAI score less than 150 points) will be evaluated as a key secondary endpoint. Safety will be assessed by recording of adverse events, clinical laboratory parameters, vital signs and electrocardiogram (ECG). Population pharmacokinetics will evaluate the two doses of GSK1605786A. Health outcomes assessments will include changes in Inflammatory Bowel Disease Questionnaire (IBDQ), Short Form-36 version 2 (SF-36v2), EQ-5D and Work Productivity and Activity Impairment-CD (WPAI-CD) and receipt of disability.